Benjamin P. Saylor

The regimen was associated with an approximately 2.5-year absolute benefit in median radiographic progression-free survival versus standard care.

Sanofi Pasteur recently announced that it is discontinuing its BCG products TheraCys and ImmuCyst, prompting fears of a shortage of BCG for bladder cancer patients. In this interview, Dr. Benjamin J. Davies, associate professor of urology at the University of Pittsburgh School of Medicine, discusses the implications of the announcement and what’s next for patients and clinicians.

A retrospective analysis looks at the short-term morbidity associated with transfusion among patients in the National Surgical Quality Improvement database.

To guide you through the 2016 AUA annual meeting and help maximize your time, Urology Times’ editorial board has reviewed the program to identify the key trends and noteworthy research at this year’s meeting.

A novel oral TRT agent, bladder control system, and localized prostate cancer agent are among other treatments in the pipeline discussed in this round-up.

Also look for coverage of products in the pipeline for bladder pain syndrome/interstitial cystitis, prostate cancer, and male infertility.

Other pipeline products discussed in this article include an immunotherapy for metastatic bladder cancer, a treatment for lower urinary tract symptoms of BPH, and an investigational clear cell renal cell carcinoma treatment.

Other pipeline products discussed in this article include agents for urinary catheter blockage, prostate cancer, bladder cancer, and overactive bladder.

A prostate cancer vaccine and an infertility diagnostic tool are among the other pipeline products discussed in this round-up.

OnabotulinumtoxinA (Botox) appears to offer long-term benefits in patients with neurogenic detrusor overactivity, recent study results indicate.

An immune checkpoint inhibitor provides “a real opportunity to change clinical practice” for patients with metastatic renal cell carcinoma, a study author says.

In this installment of "Product Preview," also look for information on products in the pipeline for renal cell carcinoma and interstitial cystitis.

Urology Times’ “Best of AUA 2015” report provides a guide to the meeting’s take-home messages in 15 therapeutic areas-an information-packed, condensed summary of the top papers and presentations.

Uroplasty, Inc. announced that Cigna has written a positive coverage policy for percutaneous tibial nerve stimulation delivered via Uroplasty's Urgent PC neuromodulation system for treatment of overactive bladder and associated symptoms of urinary urgency, urinary frequency, and urge incontinence.

Blood vessel calcification may increase risk of heart disease in patients with recurrent kidney stones, according to a recent study.

The adage, “If at first you don’t succeed, try, try again,” does not appear to hold true when it comes to anticholinergic drug use in overactive bladder patients with urinary incontinence, recent study results indicate.

Drugs and devices in the pipeline from Actavis, Genomic Health, Lipella Pharmaceuticals, Polaris Group, Innocrin Pharmaceuticals, OncoGenex Pharmaceuticals, Heat Biologics, Repros Therapeutics, and Sophiris Bio.

Kidney cancer patients were more likely to undergo partial nephrectomy when treated in hospitals that were early adopters of robotic surgery, according to a recent report that one leading expert calls “some of the best evidence to date of a favorable impact of surgical robots in urologic care.”

Autologous pubovaginal slings are associated with a high success rate following synthetic midurethral sling failure, according to recently published data.

Blue light cystoscopy with hexaminolevulinate HCl (HAL-BLC) should be considered for initial diagnosis of nonmuscle-invasive bladder cancer, an expert panel of urologists recently concluded.

New urology products and services from Symtelligence Medical Informatics, LABORIE, Metamark Genetics, the MediSafe Project, and Olympus

Men with even mild lower urinary tract symptoms are at an increased risk of developing components of cardiometabolic disorders.

As research reveals more associations between cardiometabolic disorders and urologic disease, experts are emphasizing the importance of the urologist in detecting cardiometabolic risk factors in patients.

Aggressive treatment for early-stage bladder cancer does not appear to benefit patients with the disease and may even increase the likelihood for later intervention compared with less-intensive treatment.